Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.72 |
| ▸ | KIT | P10721 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.72 |
| ▸ | FLT1 | P17948 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112134 | 0.89 | CYP2C19 (0.57) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL2112403 | 0.87 | CYP3A4 (0.74) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267263 | 0.85 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1887615 | 0.84 | CYP2C19 (0.80) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1890600 | 0.84 | CYP2C19 (0.80) | CSF1RKITCYP2C19LCKPGR | |
| Pexidartinib SCHEMBL29380288 | 0.84 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| Pexidartinib SCHEMBL29361827 | 0.84 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| Pexidartinib SCHEMBL1267310 | 0.84 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1883320 | 0.84 | CYP2C19 (1.00) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267803 | 0.83 | CYP2C19 (0.75) | CSF1RKITCYP2C19LCKPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | claimed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CSF1R 121/4885KIT 31/4885CYP2C19 3085/4885 |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CSF1R 121/4885KIT 31/4885CYP2C19 3085/4885 |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CSF1R 121/4885KIT 31/4885CYP2C19 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.